Natural Product (NP) Details

General Information of the NP (ID: NP7649)
Name
Antineoplaston A10
Synonyms
Antineoplaston A10; Antineoplaston A 10; 91531-30-5; UNII-16VY3TM7ZO; N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide; atengenal; 16VY3TM7ZO; ANTINEOPLASTON A-10; A-10; Antineoplaston-A10; A 10; Cengenal; 3-(N-Phenylacetylamino)-2,6-piperidinedione; N-(2,6-Dioxo-3-piperidinyl)benzeneacetamide; 3-((Phenylacetyl)amino)-2,6-piperidinedione; Antineoplaston A10 capsules; ANP-A10; A10; CHEMBL1980825; SCHEMBL20772654; DTXSID00919683; ZINC1590366; MFCD26961095; NSC619130; N-(6-Hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2-phenylethanimidic acid; DB11702; NSC-619130; SB19788; NCI60_005691; HY-128553; CS-0095862; N-[(3s)-2,6-dioxo-3-piperidyl]-2-phenyl-acetamide; Q27251844; Benzeneacetamide, N-(2,6-dioxo-3-piperidinyl)-, (S)-
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Brain cancer [ICD-11: 2A00] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.262
 
MDCK Permeability
 -4.215
 
PAMPA
 -
 
HIA
 - - -
 
Distribution
VDss
 -0.23
 
PPB
 40%
 
BBB
 -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 ++
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - - -
 
Excretion
CLplasma
 5.065
 
T1/2
 1.081
Toxicity
DILI
 +
 
Rat Oral Acute Toxicity
 -
 
FDAMDD
 - -
 
Respiratory
 - -
 
Human Hepatotoxicity
 - -
 
Ototoxicity
 - -
 
Drug-induced Nephrotoxicity
 +
 
Drug-induced Neurotoxicity
 ++
 
Hematotoxicity
 - -
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C13H14N2O3
PubChem CID
56260
Canonical SMILES
C1CC(=O)NC(=O)C1NC(=O)CC2=CC=CC=C2
InChI
1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1
InChIKey
OQGRFQCUGLKSAV-JTQLQIEISA-N
CAS Number
CAS 91531-30-5
Herb ID
HBIN016376
TTD Drug ID
D04QRG
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cis-diamminedichloroplatinum      Ovarian cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model KIM-1 CVCL_7969 Adult hepatocellular carcinoma Homo sapiens
                    In-vivo Model The KIM-1 cell suspension was implanted subcutaneously in BALB/c athymic mice.
                    Experimental
                    Result(s)		 The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma.
References
Reference 1 Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D. 2004;5(6):315-26.
Reference 2 The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma. Jpn J Cancer Res. 1992 May;83(5):527-31.
 Download Picture         KEGG Link